Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 5/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.49 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30771367 | 0.91 | ROCK1 (0.59) | AKT1ROCK1ROCK2MYLK4TACR3 | |
| SCHEMBL30771333 | 0.91 | ROCK1 (0.59) | AKT1ROCK1ROCK2MYLK4TACR3 | |
| SCHEMBL30771354 | 0.91 | ROCK1 (0.59) | AKT1ROCK1ROCK2MYLK4TACR3 | |
| SCHEMBL26698237 | 0.91 | ROCK1 (0.59) | AKT1ROCK1ROCK2MYLK4TACR3 | |
| SCHEMBL26698220 | 0.91 | ROCK1 (0.59) | AKT1ROCK1ROCK2MYLK4TACR3 | |
| SCHEMBL30771274 | 0.86 | ROCK1 (0.54) | AKT1ROCK1ROCK2MAPK1 | |
| SCHEMBL30771302 | 0.85 | ROCK1 (0.49) | AKT1ROCK1ROCK2MYLK4TACR3 | |
| SCHEMBL30771350 | 0.85 | ROCK1 (0.53) | AKT1ROCK1ROCK2 | |
| SCHEMBL30771298 | 0.84 | ROCK1 (0.50) | AKT1ROCK1ROCK2 | |
| SCHEMBL30771316 | 0.83 | ROCK2 (0.50) | AKT1ROCK1ROCK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4532484-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-119173509-A | ROCK inhibitors and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2023226965-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | AKT1 47/4885ROCK1 1/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.